MedTrace Logo

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

NCT02949908 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2019-01-18

Study results available
· View outcomes & findings →

Summary

This is a prospective, multicenter, open label, uncontrolled, non-interventional, single arm study to measure treatment satisfaction of relapsing remitting MS (RRMS) participants on Rebif after discontinuing initial first-line treatment.

Conditions

Interventions

DRUG

Rebif

Participants diagnosed with RRMS who had discontinued their oral or injectable first-line multiple sclerosis (MS) medication, and have been receiving subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif) were observed during the study. Participants received Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information.

Sponsors & Collaborators

  • Merck B.V., Netherlands

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Responsible · Merck B.V., the biopharmaceutical division of Merck KGaA, Darmstadt, Germany

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-09
Primary Completion
2017-08-25
Completion
2017-08-25

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02949908 on ClinicalTrials.gov